Fintel reports that on May 15, 2025, William Blair downgraded their outlook for NV5 Global (NasdaqGS:NVEE) from Outperform to ...

Fintel reports that on May 15, 2025, William Blair downgraded their outlook for Nkarta (NasdaqGS:NKTX) from Outperform to ...

On a mission to expand its recently approved Tryngolza beyond the rare genetic disorder familial chylomicronemia syndrome ...

Fintel reports that on May 5, 2025, William Blair initiated coverage of Roper Technologies (NasdaqGS:ROP) with a Outperform recommendation. Analyst Price Forecast Suggests 14.18% Upside As of April 24 ...

Nkarta Inc. (NASDAQ:NKTX) on Wednesday reported a first-quarter loss of 43 cents per share, beating the consensus loss of 44 ...

Fintel reports that on May 1, 2025, William Blair downgraded their outlook for Becton, Dickinson and (NYSE:BDX) from ...

William Blair Small-Mid Cap Growth Fund earns a Below Average Process Pillar rating. The process benefits from low expenses across its parent firm's funds, whose fees rank in their respective ...

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are ...

On Thursday, William Blair analysts adjusted their stance on Nkarta Inc. (NASDAQ: NKTX), moving from an Outperform rating to Market Perform. The firm’s analysts cited concerns over the company ...